Teicoplanin
J01X - Other antibacterials
ATC J01XA02
Unknown
JFDA label: Targocid Vial
Mechanism of Action
Disrupting Agent of Peptidoglycan — Peptidoglycan disrupting agent
| Target | Action | Gene / class |
|---|---|---|
| Peptidoglycan efficacy | DISRUPTING AGENT |
Indications
Approved
- Bacterial Infections — bacterial disease
Off-label
- Infections
- Osteomyelitis
- Skin Diseases
Antimicrobial Spectrum
Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: EUCAST v16 · curated.
Bacteria
| Organism | Activity | MIC |
|---|---|---|
| Coagulase-negative staphylococci | Susceptible | 4.0 mg/L |
| Enterococcus faecalis | Susceptible | 2.0 mg/L |
| Enterococcus faecium | Susceptible | 2.0 mg/L |
| Enterococcus spp. | Susceptible | 2.0 mg/L |
| Staphylococcus aureus | Susceptible | 2.0 mg/L |
| Streptococcus A/B/C/G | Susceptible | 2.0 mg/L |
| Streptococcus pneumoniae | Susceptible | 2.0 mg/L |
| Viridans group streptococci | Susceptible | 2.0 mg/L |
| Staphylococcus aureus | Resistant | 2.0 mg/L |
Class profile
| gramStatus | Gram+ |
|---|---|
| spectrumBreadth | Narrow |
| atypicalCoverage | No |
| isBactericidal | 1 |
| moaCategory | Cell wall synthesis inhibitor (glycopeptide, D-Ala-D-Ala binding) |
| pdIndex | Time-dependent |
| postAntibioticEffect | Short |
| mrsaCoverage | 1 |
| resistanceMechanisms | VanA gene cluster (high-level resistance),Cell wall thickening (VISA phenotype) |
Pregnancy & Lactation
Pregnancy
Lactation
Caution
Hale L3
RID 1.4%
Until more information becomes available, monitor the breastfed infant for gastrointestinal disturbances such as diarrhea, particularly in newborn and preterm infants.
LactMed: monitor the infant.
Monitoring
| Efficacy | Culture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin) |
|---|---|
| Toxicity | Renal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea) |
| Clinical pearl | Culture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship). |
| Counseling | Complete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h. |
Chemistry & Properties
| Formula | C88H97Cl2N9O33 |
|---|---|
| Molecular weight | 1879.7 g/mol |
| IUPAC name | (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid |
| CAS | 61036-62-2 |
| PubChem CID | 133065662 |
| InChIKey | BJNLLBUOHPVGFT-CAYRISATSA-N |
| logP | 0.5 (XLogP 0.5) |
| Polar surface area | 662.0 Ų |
| H-bond acceptors / donors | 34 / 24 |
SMILES
CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)OBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|---|
| Half-life | 7.13 h |
| Volume of distribution | 0.214 L/kg |
| Protein binding | 91.4% |
| BBB penetrant | No |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2B6 | Inhibitor | — |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (13)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| TALINAC 200mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 200 mg | 1 amp pack varies | Al Hilal Drug Store | — |
| TALINAC 200mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 200 mg | 10 amp pack varies | Al Hilal Drug Store | — |
| TALINAC 200mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 200 mg | 50 amp pack varies | Al Hilal Drug Store | — |
| TALINAC 400mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 400 mg | 1 amp pack varies | Al Hilal Drug Store | — |
| TALINAC 400mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 400 mg | 10 amp pack varies | Al Hilal Drug Store | — |
| TALINAC 400mg/vial, Powder and solvent for Solution for Injection or Infusion | Infusion 400 mg | 50 amp pack varies | Al Hilal Drug Store | — |
| TEICODIS 200 | Vial Teicoplanin 200 mg | 1 vial | Professional Drug Store | — |
| TEICODIS 400 | Vial Teicoplanin 400 mg | 1 vial | Professional Drug Store | — |
| Targocid | Tablet 400 mg | 1 ampoule | Ulfa Pharma Co. | — |
| Targocid Vial | Vial 200 mg/3 ml | 1 amp | Ulfa Pharma Co. | — |
| Targoplanin 200mg Lyophilised mass in vial (I.V/I.M/I.P) | Vial 200 mg | 1 vial | Hikma Pharmaceuticals Co.Ltd/Jordan | — |
| Teco 200mg Powder For Solution For Injection | Powder for Injection 200 mg | 1 vial | ORIENT DRUG STORE CO | — |
| Ticopex 200mg/Vial Powder for solution For Inj | Powder for Injection 200 mg | 1 vial | MS PHARMA/JORDAN | — |